Advertisement
Australia markets closed
  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     
  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     
  • AUD/USD

    0.6697
    +0.0017 (+0.25%)
     
  • OIL

    79.98
    +0.75 (+0.95%)
     
  • GOLD

    2,420.50
    +35.00 (+1.47%)
     
  • Bitcoin AUD

    99,884.00
    +2,643.92 (+2.72%)
     
  • CMC Crypto 200

    1,366.30
    -7.55 (-0.55%)
     
  • AUD/EUR

    0.6158
    +0.0019 (+0.30%)
     
  • AUD/NZD

    1.0911
    +0.0005 (+0.05%)
     
  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     
  • NASDAQ

    18,546.23
    -11.73 (-0.06%)
     
  • FTSE

    8,420.26
    -18.39 (-0.22%)
     
  • Dow Jones

    40,003.59
    +134.21 (+0.34%)
     
  • DAX

    18,704.42
    -34.39 (-0.18%)
     
  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     
  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

EMERYVILLE, Calif., May 03, 2024--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Date/Time:

Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT

Pre-Registration:

Participants can pre-register for the conference call here:

Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

Dial In:

Those who choose not to pre-register can access the live conference call by dialing the following and requesting conference call ID# 85516:

888-500-3691 from within the U.S.

646-307-1951 from outside the U.S.

The live webcast of the conference call also will be available on the Events section of the Company website. A replay of the call will be available beginning three hours after its completion through June 9, 2024 by dialing 877-660-6853 from within the U.S. or 201-612-7415 from outside the U.S., and entering conference ID 13746453. The webcast will also be archived here.

About NovaBay Pharmaceuticals, Inc:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon.com. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. More information about NovaBay is available here.

ADVERTISEMENT

Socialize and Stay Informed on NovaBays Progress
Like us on Facebook
Follow us on X
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240503632804/en/

Contacts

NovaBay
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com

Investor
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com